U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/gonadorelin.html

Gonadorelin is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use. Gonadorelin is used for the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [IC50]
Target ID: Q96P88
Gene ID: NA
Gene Symbol: GNRHR2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
FACTREL

Approved Use

Hypogonadism (diagnosis)—Gonadorelin as a single dose (gonadorelin test) is indicated for evaluation of the functional capacity and response of gonadotropes in the anterior pituitary in postpubertal patients who are suspected of having gonadotropin deficiency, whether due to hypothalamic function impairment alone or in combination with anterior pituitary function failure.

Launch Date

1982
Primary
FACTREL

Approved Use

Amenorrhea treatment

Launch Date

1982
PubMed

PubMed

TitleDatePubMed
Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone, and prolactin in men.
2003 Oct
Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation.
2005 Aug
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: subcutaneous route is possible
Usual Adult Dose for Gonadotropin Deficiency 0.1 mg injected once subcutaneously or intravenously as a single dose. Usual Adult Dose for Amenorrhea 5 mcg every 90 minutes (range of 1 to 20 mcg) delivered intravenously by a pump over 1 minute, every ninety minutes for 21 days.
Route of Administration: Intravenous
In Vitro Use Guide
47 ng/ml Gonadorelin induced luteinizing hormone release in ovariectomized estrogen/progesterone-treated rat at 5 ng, sc measured at 30 mins post dose by RIA (Rvb = 5.3 +/- 1.5 ng/ml)
Substance Class Protein
Created
by admin
on Sat Dec 16 00:36:41 GMT 2023
Edited
by admin
on Sat Dec 16 00:36:41 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
L8CRY8PWF2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GONADORELIN DIACETATE TETRAHYDRATE
GREEN BOOK   MI   WHO-DD  
Common Name English
GONADORELIN (GNRH) DIACETATE TETRAHYDRATE
Common Name English
Gonadorelin diacetate tetrahydrate [WHO-DD]
Common Name English
LUTRELEF
Brand Name English
LUTEINIZING HORMONE RELEASING FACTOR DIACETATE TETRAHYDRATE
Common Name English
GONADORELIN DIACETATE [MI]
Common Name English
FERTAGYL
Brand Name English
LUTREPULSE
Brand Name English
GONADORELIN DIACETATE TETRAHYDRATE [GREEN BOOK]
Common Name English
HYPOCRINE
Brand Name English
CYSTORELIN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1910
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
CFR 21 CFR 522.1075
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT000983
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY
FDA UNII
L8CRY8PWF2
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY
RXCUI
1298838
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY RxNorm
DAILYMED
L8CRY8PWF2
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY
EVMPD
SUB128680
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY
NCI_THESAURUS
C97487
Created by admin on Sat Dec 16 00:36:41 GMT 2023 , Edited by admin on Sat Dec 16 00:36:41 GMT 2023
PRIMARY
Related Record Type Details
STARTING MATERIAL -> INGREDIENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL